Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

BACKGROUND: Pain is one of the most important domains affecting health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Secukinumab has demonstrated rapid and sustained improvements in signs and symptoms, including HRQoL, among patients with active PsA. This analysis evalu...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Arthritis Res Ther
Prif Awduron: McInnes, Iain B., Mease, Philip J., Schett, Georg, Kirkham, Bruce, Strand, Vibeke, Williams, Nicole, Fox, Todd, Pricop, Luminita, Jugl, Steffen M., Gandhi, Kunal K.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2018
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5992664/
https://ncbi.nlm.nih.gov/pubmed/29880010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-018-1610-3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg